• Home

Global Immune Checkpoint Inhibitors Market Outlook 2022: NSCLC & Melanoma Showing Greatest Contributions to the IO Market

SOURCE Research and Markets

DUBLIN, Oct. 21, 2019 /PRNewswire/ -- The "Global Immune Checkpoint Inhibitors Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global immune checkpoint inhibitors market is anticipated to cross US$ 25 Billion by 2022

The report provides a detailed analysis of the global immune checkpoint inhibitors market. The report also provides the current and forecasted market for immune checkpoint inhibitors.

Given the wealth of potential targets to overcome tumor-induced immune suppression, many novel active immunotherapies are in clinical development across a range of solid tumor types. The most advanced in development are checkpoint inhibitors. These checkpoint inhibitors have dramatically altered the natural history of hard-to-treat cancers by producing substantial clinical benefits for certain tumor types and patients.

Some of these checkpoints are called PD-1, PD-L1, and CTLA-4 receptors. They work by activating the body's immune system against antigens expressed on tumor cells. Drugs that target these checkpoints hold great promise and have generated a tremendous interest in further developing and exploring these strategies across the oncology disease spectrum.

The global immune checkpoint inhibitors market has been segmented on the basis of type of product into PD-1, PD-L1, and CTLA-4. According to the report, PD-1 segment was estimated to account for the largest share in 2016 due to entry of multiple pharmaceutical players in the PD-1 inhibitors market, increasing investments from various key pharmaceutical companies and active research with many pharmaceutical companies looking to launch there products.

On the basis of type of cancer, the immune checkpoint inhibitors market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immune checkpoint inhibitors market.

A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immune checkpoint inhibitors programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.

Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immune checkpoint inhibitors market. Moreover, the report provides the sales of commercialized immune checkpoint inhibitors.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Immune Checkpoint Inhibitors: Overview

4. Market Dynamics

4.1 Drivers

4.1.1 Increasing Cancer Incidences

4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth

4.1.3 Growing Geriatric Population

4.1.4 High Healthcare Spending in Developed Economies

4.1.5 Strong Pipeline

4.1.6 Increasing Efficacy in a Wide Variety of Indications

4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products

4.2 Challenges

4.2.1 Increasing Number of Side-Effects Post Immunotherapy Treatments

4.2.2 Sky-High Development Costs of Cancer Immunotherapies

4.2.3 High Cost of Treatment

4.2.4 Lack of Awareness

4.3 Opportunities

4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity

4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival

4.3.3 Small Companies Offering Huge Opportunities for Next Generation Immunotherapies

5. Global Immune Checkpoint Inhibitors Market Outlook 2022

6. Global Immune Checkpoint Inhibitors Sales, by Product Class

6.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)

6.1.1 Yervoy (Ipilimumab)

6.2 PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand

6.2.1 Tecentriq (Atezolizumab)

6.2.2 Bavencio (Avelumab)

6.2.3 Imfinzi (Durvalumab)

6.2.4 Opdivo (Nivolumab)

6.2.5 Keytruda (Pembrolizumab)

7. Application of Immune Checkpoint Inhibitors in Major Indications

7.1 Head & Neck Cancer

7.2 Lung Cancer

7.3 Melanoma

7.4 Lymphoma

7.5 Leukemia

7.6 Others

8. Trends & Developments

8.1 Lucrative Investment Trend

8.2 Emergence of Targeted and Combination Therapies

8.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market

8.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers

9. Strategic Collaborations & Alliances in the Immune Checkpoint Inhibitors Market

10. Pipeline Analysis of Immune Checkpoint Inhibitors

11. Key Players Analysis

11.1 Genentech, Inc. (A Member of the Roche Group)

11.2 CureTech Ltd.

11.3 NewLink Genetics Corporation

11.4 Novartis AG

11.5 Bristol-Myers Squibb

11.6 Merck & Co., Inc.

11.7 AstraZeneca Plc

11.8 Pfizer Inc

11.9 Ono Pharmaceutical Co., Ltd.

11.10 EMD Serono, Inc.

For more information about this report visit

https://www.researchandmarkets.com/r/99di3e

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/global-immune-checkpoint-inhibitors-market-outlook-2022-nsclc--melanoma-showing-greatest-contributions-to-the-io-market-300942026.html

©2017 PR Newswire. All Rights Reserved.

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklymedia.com